
RGNX
Regenxbio Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.910
Open
8.850
VWAP
--
Vol
936.00K
Mkt Cap
423.77M
Low
8.270
Amount
--
EV/EBITDA(TTM)
--
Total Shares
49.26M
EV
155.90M
EV/OCF(TTM)
--
P/S(TTM)
2.73
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
82.23M
+287.64%
--
--
110.02M
+354.69%
--
--
40.87M
+83.3%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for REGENXBIO Inc. (RGNX) for FY2025, with the revenue forecasts being adjusted by 2.91% over the past three months. During the same period, the stock price has changed by -12.49%.
Revenue Estimates for FY2025
Revise Upward

+2.91%
In Past 3 Month
Stock Price
Go Down

-12.49%
In Past 3 Month
9 Analyst Rating

273.72% Upside
Wall Street analysts forecast RGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGNX is 31.43 USD with a low forecast of 21.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy

273.72% Upside
Current: 8.410

Low
21.00
Averages
31.43
High
50.00

273.72% Upside
Current: 8.410

Low
21.00
Averages
31.43
High
50.00
Goldman Sachs
Paul Choi
Hold
Maintains
$14 → $12
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$14 → $12
2025-04-17
Maintains
Hold
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$34
2025-03-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$34
2025-03-21
Reiterates
Strong Buy
Reason
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$52
2025-03-20
Reason
Chardan Capital
Daniil Gataulin
Price Target
$52
2025-03-20
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$34
2025-03-20
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$34
2025-03-20
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$36 → $34
2025-03-17
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$36 → $34
2025-03-17
Maintains
Strong Buy
Reason
Morgan Stanley
Judah Frommer
Buy
Maintains
$22 → $24
2025-03-14
Reason
Morgan Stanley
Judah Frommer
Price Target
$22 → $24
2025-03-14
Maintains
Buy
Reason
Morgan Stanley analyst Judah Frommer raised the firm's price target on Regenxbio to $24 from $22 and keeps an Overweight rating on the shares. The BLA for RGX-121 has been submitted, notes the analyst, who thinks Regenxbio remains in a "strong position" to commercialize RGX-121 and complete pivotal readouts for RGX-314 and RGX-202.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Regenxbio Inc (RGNX.O) is -8.97, compared to its 5-year average forward P/E of 2.30. For a more detailed relative valuation and DCF analysis to assess Regenxbio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
2.30
Current PE
-8.97
Overvalued PE
23.15
Undervalued PE
-18.55
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
12.84
Overvalued EV/EBITDA
3.60
Undervalued EV/EBITDA
-7.66
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
6.29
Current PS
1.52
Overvalued PS
9.64
Undervalued PS
2.94
Financials
Annual
Quarterly
FY2025Q1
YoY :
+469.79%
89.01M
Total Revenue
FY2025Q1
YoY :
-119.64%
12.13M
Operating Profit
FY2025Q1
YoY :
-109.61%
6.08M
Net Income after Tax
FY2025Q1
YoY :
-108.70%
0.12
EPS - Diluted
FY2025Q1
YoY :
-158.21%
32.61M
Free Cash Flow
FY2025Q1
YoY :
+32.46%
96.14
Gross Profit Margin - %
FY2025Q1
YoY :
-75.78%
-55.48
FCF Margin - %
FY2025Q1
YoY :
-101.68%
6.83
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
163.1K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
216.6K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.7M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
14.1K
Volume
Months
6-9
1
332.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
163.1K
USD
1
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
216.6K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RGNX News & Events
Events Timeline
2025-06-16 (ET)
2025-06-16
12:53:06
BofA expects no changes for Regenxbio regimen after competitor safety issue

2025-06-05 (ET)
2025-06-05
07:10:17
Regenxbio's RGX-202 shows efficacy in Phase 1/2 Duchenne trial

2025-05-19 (ET)
2025-05-19
16:09:07
Regenxbio signs strategic royalty monetization agreement for up to $250M

Sign Up For More Events
Sign Up For More Events
News
9.0
07-10PRnewswireREGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy
8.5
06-13SeekingAlphaREGENXBIO registers 268K shares for resale
4.5
06-05BenzingaCrude Oil Moves Higher; Ciena Posts Downbeat Earnings
Sign Up For More News
People Also Watch

OIS
Oil States International Inc
5.810
USD
-0.51%

ALF
Centurion Acquisition Corp
10.570
USD
+0.61%

USCB
USCB Financial Holdings Inc
17.760
USD
-4.05%

MBAV
M3-Brigade Acquisition V Corp
10.610
USD
-0.19%

BKSY
Blacksky Technology Inc
19.050
USD
-0.52%

EWCZ
European Wax Center Inc
4.650
USD
-3.73%

RM
Regional Management Corp
31.190
USD
-1.73%

BWB
Bridgewater Bancshares Inc
16.060
USD
-2.67%

ENGN
enGene Holdings Inc
3.450
USD
-5.22%
FAQ

What is Regenxbio Inc (RGNX) stock price today?
The current price of RGNX is 8.41 USD — it has decreased -4.32 % in the last trading day.

What is Regenxbio Inc (RGNX)'s business?

What is the price predicton of RGNX Stock?

What is Regenxbio Inc (RGNX)'s revenue for the last quarter?

What is Regenxbio Inc (RGNX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Regenxbio Inc (RGNX)'s fundamentals?

How many employees does Regenxbio Inc (RGNX). have?
